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PURPOSE: In the current study we examined the ability of diffusion MRI (dMRI) to predict pathologic response in
pancreatic cancer patients receiving neoadjuvant chemoradiation. METHODS: We performed a prospective pilot
study of dMRI in patients with resectable pancreatic cancer. Patients underwent dMRI prior to neoadjuvant
chemoradiation. Surgical specimens were graded according to the percent tumor cell destruction. Apparent
diffusion coefficient (ADC) maps were used to generate whole-tumor derived ADC histogram distributions and
mean ADC values. The primary objective of the study was to correlate ADC parameters with pathologic and CT
response. RESULTS: Ten of the 12 patients enrolled on the study completed chemoradiation and had surgery. Three
were found to be unresectable at the time of surgery and no specimen was obtained. Out of the 7 patients who
underwent pancreaticoduodenectomy, 3 had a grade III histopathologic response (N90% tumor cell destruction), 2 had a
grade IIB response (51% to 90% tumor cell destruction), 1 had a grade IIA response (11% to 50% tumor cell destruction),
and 1 had a grade I response (N90% viable tumor). Median survival for patients with a grade III response, grade I-II
response, and unresectable disease were 25.6, 18.7, and 6.1 months, respectively. There was a significant correlation
between pre-treatment mean tumor ADC values and the amount of tumor cell destruction after chemoradiation with a
Pearson correlation coefficient of 0.94 (P=.001).Meanpre-treatmentADCwas161×10−5 mm2/s (n=3) in responding
patients (N90% tumor cell destruction) compared to 125×10−5 mm2/s (n=4) in non-responding patients (N10%viable
tumor). CT imaging showed no significant change in tumor size in responders or non-responders.CONCLUSIONS: dMRI
may be useful to predict response to chemoradiation in pancreatic cancer. In our study, tumors with a low ADC mean
value at baseline responded poorly to standard chemoradiation and would be candidates for intensified therapy.
Translational Oncology (2014) 7, 644–649Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Translational Oncology Vol. 7, No. 5, 2014 Cuneo et al. 6451. Introduction Table 1. Patient and tumor characteristicsSubject Age Stage Response * Pre ADC † Post ADC † Δ ADC OS (mo)
The majority of patients with pancreatic cancer present with unresectable
locally advanced disease. Standard of care therapy for locally advanced1 52 pT2N1M0 III 152 171 19 22.4
2 59 pT3N1M0 III 162 44.8
3 59 pT3N1M0 III 168 122 -46 25.6
4 68 pT3N0M0 I 83 185 102 26.5
5 66 pT2N0M0 IIB 140 10.0
6 64 pT4NxM0 136 3.3
7 71 pT3N1M0 IIA 119 170 51 28.6
8 55 pT4NxM0 141 178 36 12.0
9 56 pTxNxM1 181 186 5 6.1
10 50 pT3N1M0 IIB 160 179 19 10.9
* Response Criteria, I: b10% tumor cell destruction, IIA: 10–50% tumor cell destruction, IIB: 51–90%
tumor cell destruction, III: b10% viable appearing tumor cells present.
† Mean tumor ADC, units ×10−5 mm2/s determined using b values 0, 100, 500, 800 s/mm2.pancreatic cancer includes a combination of chemotherapy and radiation
therapy [1]. A challenge in the management of pancreatic cancer is the
early assessment of treatment response. Given the considerable toxicity of
chemoradiation, this knowledge would be useful for selecting the most
appropriate therapy for an individual patient.
Computed tomography detected responses in pancreatic cancer are
slow and infrequent after chemoradiation [2–4] and underestimate the
effectiveness of neoadjuvant therapy in patients with resectable disease
[5,6]. In our prior series of 74 patients with unresectable pancreatic
cancer treated with gemcitabine and radiotherapy, 11 patients (15%)
achieved a CT detected partial response by RECIST, and no one
achieved a complete response [4]. Additionally, the median time to CT
detected partial response was 4.5 months from the start of radiation
(range 1.6-19.1 months). This timing would not be useful for making
clinical decisions.Histopathologically, pancreatic cancer is characterized
by a prominent desmoplastic reaction [7]. This large amount of
connective tissue would not be expected to regress after therapy and
likely contributes to the frequent misinterpretation of scans.
Diffusion-weighted MRI (dMRI) has the potential to overcome
the weaknesses of CT imaging in patients with pancreatic cancer.
Diffusion-weighted imaging is a pulse sequence (utilizing Echo Planar
imaging or EPI sequence) that can measure the mobility of water
molecules within tissue at the cellular level [8]. The diffusion of water
in tissue can be expressed as the apparent diffusion coefficient (ADC)
which reflects overall diffusivity, and is dependent on many factors,
including water mobility in intra- and extracellular spaces, the relative
volume of these spaces, cellular membrane integrity, macromolecular
components and permeability [9]. ADC values have been correlated
with tumor cellularity in patients [10]. Low ADC values are observed
in dense and fibrotic tumors due to increased tissue cellularity and
reduced extracellular volume. Conversely, high ADC values have
been described within necrotic regions of tumors [11,12].
By distinguishing between necrotic and viable tumor, dMRI has the
potential to detect and measure cellular changes that occur in response
to successful therapies, such as chemoradiation. These changes would be
expected to be detectable prior to macroscopic changes in mass, size or
morphology since removal of tumor macromolecular debris occurs
relatively slowly. In fact, clinical studies have shown that dMRI can
predict tumor response often several months prior to detectable
radiographic changes [13–18]. Therefore, we decided to study the
effectiveness of dMRI to predict response in patients with pancreatic
cancer receiving neoadjuvant chemoradiation therapy.
2. Methods
2.1. Patients
Patients with resectable pancreatic cancer planning to undergo
neoadjuvant chemoradiation therapy were eligible for this study.
Patients had to have no contraindications to MRI, adequate renal
function, and no prior history of radiation therapy to the abdomen.
All participating subjects signed informed consent. This protocol was
approved by University of Michigan Institutional Review Board.
2.2. Study Procedures
After signing informed consent, patients underwent dMRI prior to
starting neoadjuvant chemoradiation. The type of chemotherapy anddose of radiation was not specified in the study protocol; however,
most of the patients were enrolled on an unrelated clinical trial and
received gemcitabine (1000 mg/m2 on days 1, 8, and 15) plus oxaliplatin
(85 mg/m2 on days 1 and 15) with 30 Gy in 2 Gy fractions.
2.3. Diffusion MRI
MRI scans included a fat saturated gradient recalled echo T1-
weighted sequence (without and with gadolinium), a fat-saturated fast
spin-echo T2-weighted sequence, a single shot fast spin-echo T2-
weighted sequence, a T1-weighted fat suppressed SPGR, and a
diffusion sequence. The diffusion weighted technique was single shot
diffusion weighted echo-planar with spectral selective fat suppression,
with transaxial slices performed in three orthogonal diffusion
directions over a range of b-values (0, 100, 500, and 800 s/mm2).
The same MRI scanner was used for all patients on the study. All
images were obtained with multiple slices to cover the entire tumor
volume. The tumor volume, also known as the region of interest, was
determined by consensus between an abdominalMR radiologist (H.H.)
and the primary investigator (K.C.C.). ADCmaps were generated using
software created by the University of Michigan (T.L.C., B.D.R., C.J.
G., A.R.). Histograms and median/mean ADC values were determined
for each scan.
2.4. Endpoints
The primary objective of the study was to correlate tumor ADC
levels and distributions with pathologic and CT response. Pathologic
response was graded according to the system developed by Evans [19].
A single pathologist (J.K.G.) graded each specimen based on the
percent of tumor cell destruction. CT response was based on the
change in product of the two largest tumor diameters. A secondary
objective was to correlate overall survival with pretreatment and post-
treatment ADC parameters.
2.5. Statistical Analysis
Histograms depicting the distribution of voxels within a tumor
were extracted from ADC maps which were generated from dMRI
images. The median and mean ADC values for each histogram/tumor
were determined using Excel Software (Microsoft). Pathologic
response grading was converted to numerical values of tumor cell
destruction as follows Grade I 5%, Grade IIA 30%, Grade IIB 70%,
Grade III 95%. Pearson correlation coefficient was calculated to
describe the relationship between ADC and percent tumor cell
destruction. Student’s t test was used to compare mean ADC values
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Figure 1. ADC maps obtained from patients on the study. The
region of interest (tumor) is outlined. Representative tumors with a
low (A, 119 x 10−5 mm2/s) and high (B, 168 x 10−5 mm2/s) mean
ADC are shown.
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Figure 2. Relationship between pretreatment mean tumor ADC and
subsequent histopathologic response after chemoradiation therapy.
The percentage of tumor cell destruction was converted from the
grading system described by Evans DB et al. (19) to a numerical
scale. Pearson correlation coefficient was calculated to describe the
relationship between ADC and percent tumor cell destruction.
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was considered statistically significant.
3. Results
3.1. Patient Population and Study Interventions
Between October 2008 and December 2009 we performed a study
of dMRI in patients undergoing neoadjuvant chemoradiation for
pancreatic cancer. Sixteen patients consented to the study. Four of the
patients did not have imaging due to the inability to undergo MRI or
the development of metastases prior to starting therapy. Out of the
twelve remaining patients, 10 had surgery, one developed metastasis
during treatment, and one passed away prior to surgery. Out of the
patients who went to surgery, three were found to be unresectable at
the time of their operation and seven patients successfully underwent
pancreaticoduodenectomy.
The median time from the pretreatment dMRI to the start of
chemoradiation was 3.5 days (range, 1–63). Pathologic response
measured as percent tumor cell destruction was graded by a
pathologist (JKG) (Table 1). There was one Grade I response
(N90% viable tumor), one Grade IIA response (11–50% tumor cell
destruction), two Grade IIB responses (51–90% tumor cell
destruction), and three Grade III responses (minimal viable tumor).3.2. Correlation of ADC Parameters and Tumor Response
We determined the mean ADC for each tumor prior to treatment
with neoadjuvant chemoradiation. The mean pretreatment ADC for
the entire group was 144.2 × 10−5 mm2/s (SD 27.9). Representative
images of a tumor with a low ADC value and a high ADC value are
shown in Figure 1. There was a significant direct linear correlation
between pre-treatment ADC and percent tumor cell destruction with
a Pearson’s r coefficient of 0.94 (P = .001) and an R2 value of 0.90
(Figure 2). Analysis on ADC histograms for each tumor further
demonstrated that tumors with increased tumor cell destruction from
chemoradiotherapy were shifted towards higher ADC values (Figure 3).
ADChistograms were approximately 150 × 10−5 mm2/sec in width for
each tumor. The tumors with the least amount of cellular destruction
after chemoradiation demonstrated a high degree of restricted diffusion
at baseline or low ADC values. Responsive tumors had mean ADCs
above 150 × 10−5 mm2/s with a minimal amount of voxels below an
ADC of 100 × 10−5 mm2/sec.
Mean pretreatment ADC was significantly higher in patients who
had a pathologic response defined as minimal (b10%) viable tumor
(ADC 161 × 10−5 mm2/s +/−5, n = 3) compared to patients with a
poor pathologic response (ADC 125 × 10−5 mm2/s +/−16, n = 4). In
contrast, there was no significant change in tumor size seen on CT
imaging obtained prior to and after chemoradiation in responding or
non-responding patients (Figure 4).
3.3. Relationship of Tumor Cell Destruction and ADC
with Survival
Patients who had N90% tumor cell destruction (Grade III response)
had a median survival of 25.6 months, whereas patients who had greater
than 10% viable tumor remaining (Grade I-IIB response) after
chemoradiation had a median survival of 18.7 months. Patients with
unresectable tumors had a median survival of 6.1 months. All patients
with a mean pretreatment tumor ADC of b145 had either viable tumor
remaining after chemoradiation or were unresectable. Three of the five
patients with an ADC N145 x 10−5 mm2/s underwent surgery and were
found to have minimal viable tumor remaining after chemoradiation.
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Figure 3. Pretreatment ADC histograms generated for each tumor
with the corresponding amount of tumor cell destruction (percent-
age listed) seen after chemoradiation therapy and surgical
resection. A shift towards a higher ADC value was associated
with improved pathologic response to chemoradiation.
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Due to the high prevalence of metal biliary stents in our patient
population and the potential artifact on diffusion weighted sequences,
we tested three metal biliary stents to determine the feasibility of
including these patients on dMRI studies. Two nitinol (nickel
titanium alloy) MRI compatible stents were compared to a standard
stainless steel stent in a water phantom to determine the amount of
artifact seen with different MRI sequences. Considerable artifact was
seen in the diffusion sequence with the stainless steel stent but not in
the nitinol containing stents (Figure 5). Mean maximum radial
distortion on dMRI scans was 3.4 mm and 3.8 mm in the nitinol
containing stents versus 11.8 mm in the stainless steel stent.
Additionally, the nitinol containing stents produced minimal torque
in T2 or diffusion weighted sequences.
4. Discussion
In the current study, we found an association between pretreatment
tumor ADC values and subsequent tumor response to chemoradi-
ation in patients with pancreatic cancer. There was a significant
correlation between pre-treatment mean tumor ADC values and the
percent tumor cell destruction observed at the time of surgery.
Additionally, analysis of pretreatment ADC histograms for each
tumor demonstrated a shift towards higher ADC values in tumors
that later responded to treatment. These preliminary findings suggest
dMRI may be useful as an imaging biomarker in pancreatic cancer.An early imaging biomarker for patients with pancreatic cancer is
greatly needed. Treatment with chemoradiation is associated with
considerable toxicity and a poor outcome for many patients
[1,20,21]. By identifying either before treatment or part way into a
treatment course if a patient is responding, we have the potential to
adapt therapy. Patients with nonresponding tumors can have therapy
intensified or modified. Additionally, dMRI could be useful to
determine if patients are resectable after chemoradiation therapy. For
patients who are borderline resectable, it is likely some become
resectable after chemoradiation but are never offered surgery because
pancreatic tumors regress slowly on CT imaging [2–6]. Although
longitudinal dMRI was not accomplished in this study, additional
information related to spatially varying ADC changes within the
tumor mass could be obtained after initiation of treatment to provide
information related to tumor response and identify patients who may
be resectable despite what is seen on CT [18].
A limited number of reports have looked at dMRI in pancreatic
cancer. One retrospective study found tumors with low ADC values
at baseline responded poorly to systemic therapy, consistent with our
findings [22]. Another report found a correlation between preoper-
ative ADC values and the amount of tumor fibrosis in patients who
did not receive preoperative therapy. Tumors with a low ADC were
found to be densely fibrotic [23]. The large amount of fibrotic tissue
in pancreatic tumors may limit the delivery of radiosensitizing
systemic therapy and lower the amount of oxygen available for
radiation induced free radical formation thereby decreasing the
effectiveness of chemoradiation therapy [24].
Abdominal dMRI has several challenges compared to other sites
such as the brain or breast. Respiratory motion and organ movement
can lead to considerable distortion artifact and can make image
registration a challenge. The pancreas poses an added barrier due to
the increasing utilization of metal biliary stents. Metal stents are
preferred over plastic stents due to lower occlusion and complication
rates [25]. Recently, multiple companies have developed MRI
compatible metal stents using a nickel titanium alloy (nitinol). We
compared the artifact from a standard stainless steel stent to two
nitinol containing stents in a water phantom. The stainless steel stent
produced considerable streak artifact which would make the
interpretation and determination/quantification of ADC values
difficult. Additionally, it is unknown if stainless steel stents are safe
in patients undergoing MRI. The two nitinol stents we tested are
marketed as MRI compatible and produced minimal artifact on
diffusion-weighted sequences. This finding allows for the potential
inclusion of patients with nitinol containing biliary stents on future
studies examining dMRI.
There are several limitations to our study including the small
number of patients and the endpoints examined. This study was
designed as a feasibility study to demonstrate dMRI can be used in
patients with pancreatic cancer undergoing chemoradiation. It was
not powered to determine if diffusion metrics could be used to predict
subsequent survival. Our primary endpoint was pathologic response
according to the grading system developed by Evans et al. [19]. This
system has been utilized in prior studies and is shown to correlate with
patient outcome [19,26]. Larger studies will be required to determine
if dMRI is useful as a prognostic marker for early treatment response
stratification of patients with pancreatic cancer.
In conclusion, the use of dMRI in the management of patients
with pancreatic cancer has several exciting potential applications. In
our study we found a correlation between pretreatment mean ADC
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Figure 4. Comparison of pretreatment ADC and change in size on CT scan in patients showing a pathologic response (N90% tumor cell
destruction) and in nonresponding patients (N10% viable tumor).Mean pretreatment tumor ADCwas significantly higher in responding patients
compared to nonresponding patients. Whereas, tumor size did not change on CT imaging after treatment with neoadjuvant chemoradiation.
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Figure 5. One stainless steel and two nitinol (nickel titanium alloy) stents were placed in fixed diameter plastic cylinders to simulate a bile
duct. Stents were scanned in a water phantom with T2 and diffusion weighted MRI sequences. High levels of artifact were seen in the
diffusion sequence with the stainless steel stent but not with the nitinol containing stents.
648 Cuneo et al. Translational Oncology Vol. 7, No. 5, 2014values and subsequent tumor response. Larger studies exam-
ining the utility of this imaging modality as an early response
biomarker in patients with pancreatic cancer are underway at
our institution.
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